A narrative review of clinical evidence validating the efficacy of topiroxostat in managing hyperuricemia

Abstract

The current study conducted a critical review on available clinical evidence for topiroxostat, indicated for managing hyperuricemia in patients with or without gout. Relevant observational studies related to hyperuricemia and topiroxostat published between 2014 and 2022 were retrieved from various electronic databases based on the inclusion and exclusion criteria and using different combinations of MeSH terms. The systematic search yielded 2094 articles from various databases. Based on the inclusion and exclusion criteria, 16 articles were selected for systematic review. The review considered 16 studies on serum urate-lowering efficacy of topiroxostat and 6 studies that had evaluated the efficacy of the drug in hyperuricemia patients with chronic kidney disease. Four studies that evaluated hyperuricemia patients with cardiovascular risk and 10 studies that had evaluated adverse drug reactions linked to topiroxostat use were also considered. The literature findings validated the safety, efficacy, renoprotective effects, and reduced adverse events conferred by topiroxostat. The most common adverse event noted was gouty arthritis of mild to moderate in severity. The advantages of the drug when compared to the currently available xanthine oxidoreductase inhibitors include unique dual mechanism of action, cardiac safety, and renal protection.

Keywords

• hyperuricemia
• renoprotective
• serum uric acid
• topiroxostat
• uric acid
• xanthine oxidoreductase